Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Ellen Zhang, Albert M. Levin & L. Keoki Williams. (2019) How does race and ethnicity effect the precision treatment of asthma?. Expert Review of Precision Medicine and Drug Development 4:6, pages 337-356.
Read now
Read now
Kathryn Blake & John Lima. (2015) Pharmacogenomics of long-acting β2-agonists. Expert Opinion on Drug Metabolism & Toxicology 11:11, pages 1733-1751.
Read now
Read now
Hector Ortega, Charlene Prazma, Robert Y. Suruki, Hao Li & Wayne H. Anderson. (2013) Association of CHI3L1 in African-Americans with Prior History of Asthma Exacerbations and Stress. Journal of Asthma 50:1, pages 7-13.
Read now
Read now
Olufemi O. Desalu, Ademola E. Fawibe & Alakija K. Salami. (2012) Assessment of the Level of Asthma Control among Adult Patients in Two Tertiary Care Centers in Nigeria. Journal of Asthma 49:7, pages 765-772.
Read now
Read now
Sheldon L. Spector, Ubaldo J. Martin, Tom Uryniak & Christopher D. O'Brien. (2012) Budesonide/Formoterol Pressurized Metered-Dose Inhaler versus Budesonide: A Randomized Controlled Trial in Black Patients with Asthma. Journal of Asthma 49:1, pages 70-77.
Read now
Read now
Carlos A. Camargo$suffix/text()$suffix/text(), E. Rand Sutherland, William Bailey, Mario Castro, Steven W. Yancey, Amanda H. Emmett & David A. Stempel. (2010) Effect of increased body mass index on asthma risk, impairment and response to asthma controller therapy in African Americans. Current Medical Research and Opinion 26:7, pages 1629-1635.
Read now
Read now
Richard H. Stanford, Alicia W. Gilsenan, Ryan Ziemiecki, Xiaolei Zhou, William R. Lincourt & Hector Ortega. (2010) Predictors of Uncontrolled Asthma in Adult and Pediatric Patients: Analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). Journal of Asthma 47:3, pages 257-262.
Read now
Read now
Dennis Kim, Mark Glaum & Richard Lockey. (2009) Evaluation of combination long-acting β-2 agonists and inhaled glucocorticosteroids for treatment of asthma. Expert Opinion on Drug Metabolism & Toxicology 5:8, pages 933-940.
Read now
Read now
Articles from other publishers (27)
Yuji Oba, Sumayya Anwer, Tinashe Maduke, Tarang Patel & Sofia Dias. (2022) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2022:12.
Crossref
Crossref
Elise M. A. Slob, Levi B. Richards, Susanne J. H. Vijverberg, Cristina Longo, Gerard H. Koppelman, Mariëlle W. H. Pijnenburg, Elisabeth H. D. Bel, Anne H. Neerincx, Esther Herrera Luis, Javier Perez‐Garcia, Fook Tim Chew, Yang Yie Sio, Anand K. Andiappan, Steve W. Turner, Somnath Mukhopadhyay, Colin N. A. Palmer, Daniel Hawcutt, Andrea L. Jorgensen, Esteban G. Burchard, Natalia Hernandez‐Pacheco, Maria Pino‐Yanes & Anke H. Maitland‐van der Zee. (2021) Genome‐wide association studies of exacerbations in children using long‐acting beta2‐agonists. Pediatric Allergy and Immunology 32:6, pages 1197-1207.
Crossref
Crossref
J. Mark FitzGerald, Peter J. Barnes, Bradley E. Chipps, Christine R. Jenkins, Paul M. O'Byrne, Ian D. Pavord & Helen K. Reddel. (2020) The burden of exacerbations in mild asthma: a systematic review. ERJ Open Research 6:3, pages 00359-2019.
Crossref
Crossref
Christopher J Cates, Stefanie Schmidt, Montse Ferrer, Ben Sayer & Samuel Waterson. (2018) Inhaled steroids with and without regular salmeterol for asthma: serious adverse events. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
William W. BusseEric D. BatemanArthur L. CaplanH. William KellyPaul M. O’ByrneKlaus F. RabeVernon M. Chinchilli. (2018)
Combined Analysis of Asthma Safety Trials of Long-Acting β
2
-Agonists
. New England Journal of Medicine 378:26, pages 2497-2505.
Crossref
Crossref
Anne L Fuhlbrigge, Thomas Bengtsson, Stefan Peterson, Alexandra Jauhiainen, Göran Eriksson, Carla A Da Silva, Anthony Johnson, Tariq Sethi, Nicholas Locantore, Ruth Tal-Singer & Malin Fagerås. (2017) A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials. The Lancet Respiratory Medicine 5:7, pages 577-590.
Crossref
Crossref
Alberto PapiAdel H. MansurTetyana PertsevaKirsten KaiserTammy McIverBirgit GrotheSanjeeva Dissanayake. (2016) Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. Journal of Aerosol Medicine and Pulmonary Drug Delivery 29:4, pages 346-361.
Crossref
Crossref
Michael D. Cabana, Susan J. Kunselman, Sharmilee M. Nyenhuis & Michael E. Wechsler. (2014) Researching asthma across the ages: Insights from the National Heart, Lung, and Blood Institute’s Asthma Network. Journal of Allergy and Clinical Immunology 133:1, pages 27-33.
Crossref
Crossref
Wayne H. Anderson, Beena T. Koshy, Lingkang Huang, Michael Mosteller, Sandra W. Stinnett, Lynn D. Condreay & Hector Ortega. (2013) Genetic analysis of asthma exacerbations. Annals of Allergy, Asthma & Immunology 110:6, pages 416-422.e2.
Crossref
Crossref
Christopher J Cates, Roman Jaeschke, Stefanie Schmidt & Montse Ferrer. (2013) Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Esteban Gomez & Claudia R. Morris. (2013) Asthma Management in Sickle Cell Disease. BioMed Research International 2013, pages 1-12.
Crossref
Crossref
Randall W. Brown & Christy S. Cappelletti. (2013) Reaching Beyond Disparity: Safely Improving Asthma Control in the At-Risk African-American Population. Journal of the National Medical Association 105:2, pages 138-149.
Crossref
Crossref
Randall W. Brown, Christopher D. O'Brien, Ubaldo J. Martin, Tom Uryniak & Kathy L. Lampl. (2012) Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: A randomized controlled trial. Journal of Allergy and Clinical Immunology 130:2, pages 362-367.e9.
Crossref
Crossref
Karen E. Wells, Edward L. Peterson, Brian K. Ahmedani, Richard K. Severson, Julie Gleason-Comstock & L. Keoki Williams. (2012) The relationship between combination inhaled corticosteroid and long-acting β-agonist use and severe asthma exacerbations in a diverse population. Journal of Allergy and Clinical Immunology 129:5, pages 1274-1279.e2.
Crossref
Crossref
Kevin R. Murphy, Tom Uryniak, Ubaldo J. Martin & James Zangrilli. (2012) The Effect of Budesonide/Formoterol Pressurized Metered-Dose Inhaler on Predefined Criteria for Worsening Asthma in Four Different Patient Populations with Asthma. Drugs in R&D 12:1, pages 9-14.
Crossref
Crossref
Kevin R. Murphy, Tom Uryniak, Ubaldo J. Martin & James Zangrilli. (2012) The Effect of Budesonide/Formoterol Pressurized Metered-Dose Inhaler on Predefined Criteria for Worsening Asthma in Four Different Patient Populations with Asthma. Drugs in R & D 12:1, pages 9-14.
Crossref
Crossref
Michael E. Wechsler, Mario Castro, Erik Lehman, Vernon M. Chinchilli, E. Rand Sutherland, Loren Denlinger, Stephen C. Lazarus, Stephen P. Peters & Elliot Israel. (2011) Impact of Race on Asthma Treatment Failures in the Asthma Clinical Research Network. American Journal of Respiratory and Critical Care Medicine 184:11, pages 1247-1253.
Crossref
Crossref
Reena Khianey & John Oppenheimer. (2011) Controversies regarding long-acting β2-agonists. Current Opinion in Allergy & Clinical Immunology 11:4, pages 345-354.
Crossref
Crossref
Kwang Ha Yoo. (2011) Respiratory Review of 2011: Asthma. Tuberculosis and Respiratory Diseases 71:2, pages 81.
Crossref
Crossref
Francine M Ducharme, Muireann Ni Chroinin, Ilana Greenstone & Toby J Lasserson. (2010) Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Michael E Wechsler, Susan J Kunselman, Vernon M Chinchilli, Eugene Bleecker, Homer A Boushey, William J Calhoun, Bill T Ameredes, Mario Castro, Timothy J Craig, Loren Denlinger, John V Fahy, Nizar Jarjour, Shamsah Kazani, Sophia Kim, Monica Kraft, Stephen C Lazarus, Robert F LemanskeJrJr, Amy Markezich, Richard J Martin, Perdita Permaul, Stephen P Peters, Joe Ramsdell, Christine A Sorkness, E Rand Sutherland, Stanley J Szefler, Michael J Walter, Stephen I Wasserman & Elliot Israel. (2009) Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. The Lancet 374:9703, pages 1754-1764.
Crossref
Crossref
А. В. Емельянов & Г. Р. Сергеева. (2009) Безопасность комбинированной терапии сальметеролом
и флутиказона пропионатом у больных
бронхиальной астмой. PULMONOLOGIYA:5, pages 107-112.
Crossref
Crossref
Kate McKeage & Susan J. Keam. (2009) Salmeterol/Fluticasone Propionate. Drugs 69:13, pages 1799-1828.
Crossref
Crossref
. (2009) Long-Acting Beta-Agonists in Asthma. New England Journal of Medicine 361:2, pages 208-209.
Crossref
Crossref
Christopher J Cates, Toby J Lasserson & Roman Jaeschke. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Harold S. Nelson, Warner Carr, Robert Nathan & Jay M. Portnoy. (2009) Update on the safety of long-acting β-agonists in combination with inhaled corticosteroids for the treatment of asthma. Annals of Allergy, Asthma & Immunology 102:1, pages 11-15.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:12.
Crossref
Crossref